Related Experiment Videos

High incidence of hypertension in children presenting with acute lymphoblastic leukemia

S P Attard-Montalto1, V Saha, Y Y Ng

  • 1Department of Paediatric Oncology, St Bartholomew's Hospital, London, United Kingdom.

Insights

Hypertension is common in children with acute lymphoblastic leukemia (ALL), affecting 46% of patients at diagnosis or during treatment. Prompt management of high blood pressure in ALL patients is crucial to prevent serious complications.

Area of Science:

  • Pediatric Oncology
  • Nephrology
  • Hematology

Background:

  • Hypertension is a known complication of acute lymphoblastic leukemia (ALL), but its incidence and clinical significance in pediatric ALL are not well-established.
  • Understanding the prevalence and characteristics of hypertension in pediatric ALL is essential for optimizing patient care and preventing adverse outcomes.

Purpose of the Study:

  • To determine the incidence of hypertension in newly diagnosed pediatric patients with acute lymphoblastic leukemia (ALL).
  • To investigate the clinical presentation, management, and outcomes of hypertension in this patient population.
  • To explore the association between hypertension, renal abnormalities, and the leukemic process.

Main Methods:

  • Retrospective review of blood pressure profiles in 30 newly diagnosed pediatric ALL patients over 18 months.
  • Assessment of hypertension at presentation and during induction chemotherapy.
  • Correlation of hypertension with renal ultrasound findings and clinical symptoms.
  • Monitoring of blood pressure during follow-up after chemotherapy.

Main Results:

  • 46% (14 of 30) of pediatric ALL patients exhibited hypertension at presentation or during induction chemotherapy.
  • Hypertension was often asymptomatic, though one patient experienced generalized convulsions.
  • Four hypertensive patients showed renal enlargement on ultrasound, which resolved with hematologic remission.
  • All hypertensive patients achieved normotension at follow-up (2-18 months post-chemotherapy).

Conclusions:

  • The high incidence of hypertension in pediatric ALL suggests the leukemic process is a significant etiologic factor.
  • Chemotherapy can aggravate or unmask pre-existing hypertension in ALL patients.
  • Increased awareness and timely management of hypertension are vital to mitigate potential life-threatening complications in pediatric ALL.

Related Concept Videos